Biomarker Core

西奈山ADRC（佐野）：生物标志物核心（核心G）-研究总结 生物标志物提供了阿尔茨海默病（AD）病理特征的间接证据， AD的诊断和个体参加针对这些病理的治疗试验的可能性增加 将从干预中受益。生物标志物研究越来越有必要实现双向 翻译的努力，了解异质性的疾病，并确定弹性因素。的 拟议的生物标志物核心将巩固和支持涉及生物标志物研究的现有努力，目标是 改善早期诊断，确定恢复力指标，描述疾病异质性， 加快临床试验。生物标志物核心的目标是：1）为生物标志物提供服务 收集和分析ADRC队列，并广泛促进ADRD研究。核心会协调 使用NIH-AA研究框架（A/T/N）的ADRC队列的生物标志物表征。芯会 提供使用特定MRI序列、PET示踪剂和液体生物标志物进行采集的建议; 分析管道;以及支持项目设计的专业知识。2)促进广泛和快速的共享， 与其他核心、整个机构以及与外部机构的互动。核心将促进 用于存储和共享经处理的神经成像数据和流体样本的信息学，有助于路由生物标志物- 将参与者描述为最匹配的研究和试验，并支持开放科学的文化， 跨越机构界限的协作努力。3)利用成像生物标志物数据催化 开发创新项目，重点关注生物标志物作为疾病风险的早期指标， 异质性和弹性因素。核心将积极与研究者合作， 项目中的生物标志物，并将提供访问生物标志物特征的参与者。4)发展未来 通过生物标志物培训和参与基于项目的活动。核心将提供生物标志物培训 REC学员和ADRD研究的新研究者，与研究者协商制定项目 涉及生物标志物，并将临床ADRD研究人员与生物标志物的技术专长联系起来。跨这些 核心将强调疾病的早期阶段（临床前和轻度认知障碍），目标是 最大限度地利用现有的观测项目，并增加参与者的特点的可能性 将保留在临床试验的样本中。核心小组将优先确定 代表少数群体为健康差异研究做出贡献，并增加ADRD的普遍性 生物标志物研究这些核心活动将支持采集、分析、信息学和数据共享， 将生物标志物研究纳入ADRC的工作中，以加速对疾病异质性的理解 通过阐明与脆弱性或弹性因素相关的生物差异， 临床症状的表现。

Mount Sinai ADRC (Sano): Biomarker Core (Core G) – Research Summary Biomarkers provide indirect evidence of the pathological hallmarks of Alzheimer's disease (AD), affording earlier diagnosis of AD and increased likelihood that individuals enrolled in therapeutic trials targeting these pathologies will benefit from the intervention. Biomarker research is increasingly necessary for enabling bidirectional translational efforts, for understanding heterogeneity of the disease, and for identifying resilience factors. The proposed Biomarker Core will consolidate and bolster existing efforts involving biomarker research with the goals of improving early diagnosis, identifying indicators of resilience, characterization of disease heterogeneity, and acceleration of clinical trial efforts. The aims of the Biomarker Core are to: 1) Provide services for biomarker collection and analysis on the ADRC cohort and to facilitate ADRD research broadly. The Core will coordinate biomarker characterization of the ADRC cohort using the NIH-AA research framework (A/T/N). The Core will provide recommendations for acquisition with specific MRI sequences, PET tracers, and fluid biomarkers; analytic pipelines; and expertise to support project design. 2) Promote wide and rapid sharing through interactions with other Cores, across the institution, and with outside institutions. The Core will facilitate informatics for banking and sharing processed neuroimaging data and fluid samples, help to route biomarker- characterized participants to best-matched studies and trials, and support a culture of open science to encourage collaborative efforts across institutional boundaries. 3) Leverage imaging biomarker data to catalyze development of innovative projects focused on biomarkers as early indicators of disease risk and to characterize heterogeneity and resilience factors. The Core will actively work with investigators to optimize inclusion of biomarkers in projects and will provide access to biomarker-characterized participants. 4) Develop the future through biomarker training and involvement in project-based activities. The Core will provide biomarker training to REC trainees and to investigators new to ADRD research, consult with investigators to develop projects involving biomarkers, and will link clinical ADRD researchers to technical expertise in biomarkers. Across these aims, the Core will emphasize the early stages of disease (preclinical and mild cognitive impairment), with a goal of maximizing utility to existing observational projects and increasing the likelihood that characterized participants will remain in the sample for enrollment into clinical trials. The Core will prioritize characterization of under- represented minorities to contribute to health disparities research and increase the generalizability of ADRD biomarker research. These Core activities will support acquisition, analysis, informatics, and data sharing to integrate biomarker research into the efforts of the ADRC to accelerate understanding of disease hetereogeneity by illuminating biological differences associated with vulnerability or resilience factors that underlie the expression of clinical symptoms.